2. Ferri C., Sebastiani M., Giuggioli D., Cazzato M., Longombardo G., Antonelli A., Puccini R., Michelassi C., Zignego A.L. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin. Arthritis. Rheum. 2004;33(6):355–374.

3. Retamozo S., Diaz-Lagares C., Bosch X., Bové A., Brito-Zerón P., Gómez M.E. Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine. 2013;92(5):273–284].

4. Saadoun D., Landau D.A., Calabrese L.H., Cacoub P.P. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology. 2007;46(8):1234–1242.

5. Fabrizi F., Plaisier E., Saadoun D., Martin P., Messa P., Cacoub P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am. J. Kidney Dis. 2013;61:623–637.

6. Alric L., Plaisier E., Thebault S., Péron J.M., Rostaing L., Pourrat J., Ronco P., Piette J.C., Cacoub P. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am. J. Kidney Dis. 2004;43:617–623.

7. Ohta S., Yokoyama H., Wada T., Sakai N., Shimizu M., Kato T., Furuichi K., Segawa C., Hisada Y., Kobayashi K. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am. J. Kidney Dis. 1999;33(6):1040–1048.

8. Fabrizi F., Bruchfeld A., Mangano S., Dixit V., Messa P., Martin P. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. International Journal of Artificial Organs. 2007;30(3):212–219.

9. Stine J.G., Cornella S., Shah N.L. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann. Rheum. Dis. 2014;73:e64.

10. Sise M.E., Bloom A.K., Wisocky J., Lin M.V., Gustafson J.L., Lundquist A.L., Steele D., Thiim M., Williams W.W., Hashemi N., Kim A.Y., Thadhani R., Chung R.T. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with sofosbuvir-based direct-acting antiviral agents. Hepatology. 2016;63:408–417.

11. Saadoun D., Thibault V., Si Ahmed S.N., Alric L., Mallet M., Guillaud C., Izzedine H., Plaisier A., Fontaine H., Costopoulos M., Le Garff-Tavernier M., Hezode C., Pol S., Musset L., Poynard T., Cacoub P. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75(10):1777–1782.

12. Comarmond C., Garrido M., Pol S., Desbois A.C., Costopoulos M., Le Garff-Tavernier M., Si Ahmed S.N., Alric L., Fontaine H., Bellier B., Maciejewski A., Rosenzwajg M., Klatzmann D., Musset L., Poynard T., Cacoub P., Saadoun D. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. Gastroenterology. 2017;152(8):2052–2062.

13. EASL Recommendations on Treatment of Hepatitis C. 2016. J. Hepatol. 2017;66(1):153–194.

14. Uojima H., Kobayashi S., Hidaka H., Matsumoto S., Ohtake T., Kinbara T., Oka M., Yamanouchi Y., Kunieda T., Yamanoue H., Kanemaru T., Tsutsumi K., Fujikawa T., Hyun Sung J., Kako M. Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study. Renal. Replacement Therapy. 2017;3:7. Doi: 10.1186/s41100-016-0091-6.

15. Suda G., Kudo N., Nagasaka A., Furuya K., Yamamoto Y., Kobayashi T., Shinada K., Tateyama M., Konno J., Tsukuda Y., Yamasaki K., Kimura M., Umemura M., Izumi T., Tsunematsu S., Sato F., Terashita K., Nakai M., Horimoto H., Sho T., Natsuizaka M., Morikawa K., Ogawa K., Sakamoto N. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J. Gastroenterol. Doi: 10.1007/s00535-016-1162-8.

16. Toyoda H., Kumada T., Tada T., Takaguchi K., Ishikawa T., Tsuji K., Zeniya M., Iio E., Tanaka Y. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J. Gastroenterol. 2016;51(7):741–7. Doi: 10.1007/s00535-016-1174-4.

17. Miyazaki R., Miyagi K. Effect and safety of daclatasvir-asunaprevir combination therapy for chronic hepatitis C virus genotype 1b-infected patients on hemodialysis. Ther. Apher. Dial. 2016;20(5):462–467

18. Bruchfeld A., Lindahl K., Schvarcz R., Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther. Drug Monit. 2002;24(6):701–708.

19. Christine M.N., Mendes M., Tsunoda S., Joseph D.M. Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus. PLoS. Curr. 2011;8;3:RRN1207.

20. Инструкция к медицинскому применению препарата Сунвепра®.

21. Инструкция к медицинскому применению препарата Даклинза®.

22. Gentile I., Buonomo A.R., Zappulo E., Minei G., Morisco F., Borrelli F., Coppola N., Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther. Clin. Risk. Manag. 2014;10:493–504.

23. McPhee F., Suzuki Y., Toyota J., Karino Y., Chayama K., Kawakami Y., Yu M.L., Ahn S.H., Ishikawa H., Bhore R., Zhou N., Hernandez D., Mendez P., Kumada H. High sustained virologic response to daclatasvir pus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv. Ther. 201;32(7):637–649.

24. Сагалова О.И. Опыт применения двойной безинтерферроновой схемы в реальных клинических условиях в России. Устное выступление. Международный конгресс «Белые ночи гепатологии», Санкт-Петербург, 2017.

25. Shimada M., Nakamura N., Endo T., Yamabe H., Nakamura M., Murakami R., Narita I., Tomita H. Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report. BMC Nephrology. 2017;18:109.